This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Feuerstein's Biotech-Stock Mailbag

Thanks for returning to the Biotech Mailbag, where I try my best to answer your biotech investment questions. This week, I'll focus on Cell Genesys (CEGE), Encysive Pharmaceuticals (ENCY), Gilead Sciences (GILD) and Alexion Pharmaceuticals (ALXN).


I'll kick off the action with a note from Dore S., who writes: "Hey Adam, your faithful herd would probably appreciate an update on Cell Genesys. The company released a Feb. 15 press release that smelled like a subset analysis but has catapulted the stock. Your two cents for all to read would be appreciated."

Dore's sense of smell is pretty good. I'm not a believer in Cell Genesys, and nothing in this latest data presentation for its GVAX prostate cancer vaccine, GVAX-Prostate, compels me to change my mind.

Last week, Cell Genesys reported that researchers analyzing blood samples from prostate cancer patients in a long-ago completed phase II study found two antibody, or immune, responses to GVAX-Prostate that correlated positively with significantly longer survival.

Interesting, except for the fact that in order to find the two antigens responsible for this immune response, the researchers looked at dozens of different antigens -- including some they previously though would be linked to an immune response -- but found nothing.

What this tells us is that Cell Genesys had to go deep-sea fishing with a very large net to find some positive data to report. That's not necessarily a bad thing, but it certainly doesn't prove that GVAX-Prostate is doing what it needs to do most -- helping prostate cancer patients live longer.

Let's not forget that we've seen this game played before. Remember Genitope (GTOP)? It, too, tried to tie an immune response to its MyVax cancer vaccine to a positive clinical benefit for patients. In the end, MyVax turned out to be a dismal failure .

Cell Genesys is running two phase III studies of GVAX-Prostate right now, but that data's not expected until the second half of 2009.

Meantime, Cell Genesys needs to stay visible to investors today. What's one way to do this? Analyze old clinical trials over and over again to scrap together something "new" to say.

That helps put some pop into the stock in the near term, which is what happened over the past week. Shares were up more than 50% at one point.

As I write this Friday, the stock has slipped to around $2.62 after reaching as high as $3.36 on Thursday. Prior to this week, the stock hadn't seen the $3 level since early November.

But I don't think this week's data, or the increase in Cell Genesys' stock price, are indicative of what will happen when we finally see the phase III data on GVAX-Prostate. Like I said, I don't have high hopes for this cancer vaccine, especially in the first phase III trial. In my book, GVAX-Prostate doesn't win.


Pfizer's (PFE) decision to buy Encysive Pharmaceuticals for $195 million -- essentially spare change that the drug giant found under the cushions of its reception-area couch -- finally puts to rest to one of the more pitiful biotech sagas in recent memory.

Few companies in this oh-so-fun sector of ours have managed to rack up a record of futility quite like Encysive. There are only a handful of companies that can manage to get turned down three times by the FDA for the same drug. In this case, Encysive was never able to gets its pulmonary arterial hypertension drug Thelin approved in the U.S.

So, now that Pfizer is gobbling them up for a mere $2.35 a share, we can say goodbye and thank Encysive for all the fun we've had at its expense.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs